Maria Jose Muñoz-Alonso

Maria Jose Muñoz-Alonso

Auto-generated profile, based on publicly available information

Maria Jose Muñoz-Alonso

PharmaMar 1 Research and Development, Oncology Business Unit Madrid, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PAPablo Aviles
Pablo Aviles
MRMarcelo Ribeiro
Marcelo Ribeiro
MGMaria Jose Guillén
Maria Jose Guillén
MDMarta Martinez Diez
Marta Martinez Diez
MMMaria Jose Muñoz-Alonso
Maria Jose Muñoz-Alonso
CCCarmen Cuevas
Carmen Cuevas
This study evaluates PM534, a novel colchicine-binding domain inhibitor, for its potential in cancer therapy. PM534 exhibited potent in vitro efficacy against a panel of 14 human cancer cell lines, including breast, ovarian, and prostate cancers, with concentration needed to reduce the growth of treated cells to half that of untreated cells values in the low nanomolar range. Both continuous (72 hours) and short-term (1–24 hours) exposure led to irreversible effects, inducing G2–M cell cycle arrest and multinucleation. Additionally, PM534 also impaired angiogenic process. It effectively inhibited HUVEC functions, including adhesion, with an IC50 of 2.3 nmol/L, markedly more potent than colchicine (IC50 = 1,800 nmol/L). At concentrations as low as 1.6 nmol/L, PM534 delayed wound closure in migration assays, completely inhibiting migration above 4 nmol/L. Additionally, PM534 abrogated invasion and disrupted capillary-like network formation at concentrations starting from 0.5 nmol/L without inducing cytotoxicity. In vivo PM534 demonstrated robust antitumor efficacy across six xenograft models, including ovarian (A2780 and ES-2), triple-negative breast (MDA-MB-231 and HCC1937), and prostate (VCaP and 22Rv1) tumors. This treatment also led to statistically significant increases in median survival times across all models, without inducing signs of systemic toxicity. Mechanistically, PM534 induced apoptosis, mitotic catastrophe, and necrosis in tumor tissues. Importantly, PM534 retained efficacy in models overexpressing multidrug resistance proteins P-glycoprotein or β-III tubulin, overcoming common resistance mechanisms that limit the effectiveness of other tubulin-binding agents. Collectively, these findings highlight PM534 as a promising antitumor agent with potent activity against diverse and treatment-resistant malignancies. A phase I clinical trial (NCT#5835609) is underway to assess the therapeutic potential of PM534 in patients with advanced solid tumors.

1 June 2026
Verified
Other
Open access
PAPablo Aviles
Pablo Aviles
MRMarcelo Ribeiro
Marcelo Ribeiro
MGMaria Jose Guillén
Maria Jose Guillén
MDMarta Martinez Diez
Marta Martinez Diez
MMMaria Jose Muñoz-Alonso
Maria Jose Muñoz-Alonso
CCCarmen Cuevas
Carmen Cuevas
This study evaluates PM534, a novel colchicine-binding domain inhibitor, for its potential in cancer therapy. PM534 exhibited potent in vitro efficacy against a panel of 14 human cancer cell lines, including breast, ovarian, and prostate cancers, with concentration needed to reduce the growth of treated cells to half that of untreated cells values in the low nanomolar range. Both continuous (72 hours) and short-term (1–24 hours) exposure led to irreversible effects, inducing G2–M cell cycle arrest and multinucleation. Additionally, PM534 also impaired angiogenic process. It effectively inhibited HUVEC functions, including adhesion, with an IC50 of 2.3 nmol/L, markedly more potent than colchicine (IC50 = 1,800 nmol/L). At concentrations as low as 1.6 nmol/L, PM534 delayed wound closure in migration assays, completely inhibiting migration above 4 nmol/L. Additionally, PM534 abrogated invasion and disrupted capillary-like network formation at concentrations starting from 0.5 nmol/L without inducing cytotoxicity. In vivo PM534 demonstrated robust antitumor efficacy across six xenograft models, including ovarian (A2780 and ES-2), triple-negative breast (MDA-MB-231 and HCC1937), and prostate (VCaP and 22Rv1) tumors. This treatment also led to statistically significant increases in median survival times across all models, without inducing signs of systemic toxicity. Mechanistically, PM534 induced apoptosis, mitotic catastrophe, and necrosis in tumor tissues. Importantly, PM534 retained efficacy in models overexpressing multidrug resistance proteins P-glycoprotein or β-III tubulin, overcoming common resistance mechanisms that limit the effectiveness of other tubulin-binding agents. Collectively, these findings highlight PM534 as a promising antitumor agent with potent activity against diverse and treatment-resistant malignancies. A phase I clinical trial (NCT#5835609) is underway to assess the therapeutic potential of PM534 in patients with advanced solid tumors.

1 June 2026
Verified
Other
Open access
PAPablo Aviles
Pablo Aviles
MRMarcelo Ribeiro
Marcelo Ribeiro
MGMaria Jose Guillén
Maria Jose Guillén
MDMarta Martinez Diez
Marta Martinez Diez
MMMaria Jose Muñoz-Alonso
Maria Jose Muñoz-Alonso
CCCarmen Cuevas
Carmen Cuevas
Cell lines used and key characteristics

1 June 2026
Verified
Other
Open access
PAPablo Aviles
Pablo Aviles
MRMarcelo Ribeiro
Marcelo Ribeiro
MGMaria Jose Guillén
Maria Jose Guillén
MDMarta Martinez Diez
Marta Martinez Diez
MMMaria Jose Muñoz-Alonso
Maria Jose Muñoz-Alonso
CCCarmen Cuevas
Carmen Cuevas
A: HUVEC adhesion (% of adhesion compared to control) on an extracellular matrix composed of fibronectin and type I collagen quantified with Sulforhodamine B following 24 hours of incubation with PM534 or colchicine. Results are presented as the mean percentage (n=3). Dotted line indicates a 50% reduction of adhesion. B: Survival curves for HUVEC cells following the incubation with PM534 and colchicine, in which 70% of cell were alive at 10 nM of PM534.

1 June 2026
Verified
Other
Open access
PAPablo Aviles
Pablo Aviles
MRMarcelo Ribeiro
Marcelo Ribeiro
MGMaria Jose Guillén
Maria Jose Guillén
MDMarta Martinez Diez
Marta Martinez Diez
MMMaria Jose Muñoz-Alonso
Maria Jose Muñoz-Alonso
CCCarmen Cuevas
Carmen Cuevas
A: Changes of body weights (as mean %) of mice bearing different xenografts and treated with PM534 (blue) or placebo (gray) on days 0, 7 and 14. Data are expressed as mean±SD (n≥6/group). B: Clinical chemistry parameters obtained on Day 21 in non-tumored female nu/nu mice (n=10) after the i.v. administration of PM534 (at 5 mg/kg; days 0, 7 and 14) or placebo. C: Changes (folds) in clinical chemistry parameters of PM534-treated mice (vs. placebo: median values between parenthesis).

1 June 2026
Verified
Other
Open access
PAPablo Aviles
Pablo Aviles
MRMarcelo Ribeiro
Marcelo Ribeiro
MGMaria Jose Guillén
Maria Jose Guillén
MDMarta Martinez Diez
Marta Martinez Diez
MMMaria Jose Muñoz-Alonso
Maria Jose Muñoz-Alonso
CCCarmen Cuevas
Carmen Cuevas
Protein corrected transport rate (pmol/min/pmol transporter protein) of PM534 in Abcb1KO-MDCKII-MDR1-LV cells. Data are expressed as mean (n=3) and 95% CI.